ArticleJournal of medicinal chemistry2014
Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus.
Article in Journal of medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 105 citations in OpenAlex.
- Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.Chemical Society reviews · 2026Review
- Ligand-based discovery of novel N-arylpyrrole derivatives as broad-spectrum antimicrobial agents with antibiofilm and anti-virulence activity.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Repurposing the phenylthiazole scaffold with 1,3,4-oxadiazole for selective, potent and well-tolerated antifungal activity.RSC advances · 2025Article
- Rational design and synthesis of novel phenyltriazole derivatives targeting MRSA cell wall biosynthesis.RSC advances · 2024Article
- Synthesis and structure-activity relationship of novel thiazole aminoguanidines against MRSA andRSC medicinal chemistry · 2024Article
- Novel phenylthiazoles with aRSC advances · 2024Article
- Naphthylthiazoles: a class of broad-spectrum antifungals.RSC medicinal chemistry · 2023Article
- Exploring novel aryl/heteroaryl-isosteres of phenylthiazole against multidrug-resistant bacteria.RSC advances · 2023Article
- Expanding the structure-activity relationships of alkynyl diphenylurea scaffold as promising antibacterial agents.RSC medicinal chemistry · 2023Article
- The Anti-MRSA Activity of Phenylthiazoles: A Comprehensive Review.Current pharmaceutical design · 2022Review
- Thiazole Ring-A Biologically Active Scaffold.Molecules (Basel, Switzerland) · 2021Review
- Novel 3-Acetyl-2,5-disubstituted-1,3,4-oxadiazolines: Synthesis and Biological Activity.Molecules (Basel, Switzerland) · 2020Article
- Synergistic Effects of Thiosemicarbazides with Clinical Drugs againstMolecules (Basel, Switzerland) · 2020Article
- Aryl-alkyl-lysines: Novel agents for treatment of C. difficile infection.Scientific reports · 2020Article
- Identification of a Phenylthiazole Small Molecule with Dual Antifungal and Antibiofilm Activity Against Candida albicans and Candida auris.Scientific reports · 2019Article
- An aryl isonitrile compound with an improved physicochemical profile that is effective in two mouse models of multidrug-resistant Staphylococcus aureus infection.Journal of global antimicrobial resistance · 2019Article
- Peptidoglycan pathways: there are still more!RSC advances · 2019Review
- Article
- Discovery and Development of 8-Substituted Cycloberberine Derivatives as Novel Antibacterial Agents against MRSA.ACS medicinal chemistry letters · 2018Article
- Phenylthiazoles with tert-Butyl side chain: Metabolically stable with anti-biofilm activity.European journal of medicinal chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) infections are growing global health concerns. Structure-activity relationships of phenylthiazoles as a new antimicrobial class have been addressed. We present 10 thiazole derivatives that exhibit strong activity against 18 clinical strains of MRSA and VRSA with acceptable PK profile. Three derivatives revealed an advantage over vancomycin by rapidly eliminating MRSA growth within 6 h, and no derivatives are toxic to HeLa cells at 11 μg/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.